Medironic

INVENTION DISCLOSURE FORM

WARNING: Due to the confidential nature of this document, save it as a password protected document. Do not send this document through GroupWise.

This is a WORD Template form. Press enter or tab to move to each field. Please fill out this form as completely as possible. If the allotted space is not sufficient, use a separate sheet. Have your manager sign the form and forward it to the Patent Section of the Law Department, LC340. Please attach any drawings and technical descriptions that are available and assemble copies of the background articles, books, advertisements, etc. for use by your patent attorney.

1.	Inventor(s)	Employee	Mail	·				
	Full Name(s)	Number	Stop	Home Address (Include Zip Code)				
	Daniel Sigg	65322	B252	1485 Hoyt Ave W. Saint Paul, MN 55108				
				• •				
								
2.	Title of Invention	: <u>Nitric oxide rele</u>	asing medical dev	rice				
other powerld parts as	d by polymers cun plymer parts of me prevent clot formati ad chronically impli ssue in particular i How have others products, or othe	rently being used i dical devices (for on, but subsequer anted medical dev n the managemen addressed this pr	n most lead bodie example MCRD's' of fibrosis. The purices would ultima t of chronic pacino oblem (List and a erials you used or	nitric oxide has the ability to prevent clot formation. Nitric oxide can be a sand catheters (silicones, and polyurethanes), and conceivably from Certain formulations allow for chronic nitric oxide release which not on the polymer tely lead to enhanced REMOVABILITY of such devices, a major largely leads. Itach any patents, books, articles, devices, Medironic or competitor's which may be prior art)? See attached published references by Dr. M.				
5.	The invention is described on pages 91 of Lab Notebook No. 10191 (Please attach copy).							
6.	When was a device built which included the invention?							
	Who built it?	Where is it?	- 					
	Who has support	ing documents? _						
Who witnessed tests? When and where?								
7.	Discuss the problems which the invention is designed to solve, referring to any prior devices of a similar nature with which you may be familiar. The problem is to decrease fibrosis around the lead or catheter body, which will significantly enhance lead removability.							
8.	State the advantages of the invention over presently known devices, systems or processes. <u>Major advantage</u> , as currently there is no biologically or pharmacologically target therapy to decrease fibrosis in pacing leads.							
9.	List all known and other possible uses for the invention, <u>Lead removability</u> , use in sensors, in stents, in pacing lead MCRD's (electrodes)							
	Specifically describe the invention and its operation. You may use and attach copies of sketches, prints, photographs and illustrations which should be signed, witnessed and dated. Use numbers and descriptive names in descriptions and drawings. Either a silicone or polyurethane polymer will be manufactured which contain NO-releasing functions, such as diazenoiumdiolates. These could be synthesized, and then extruded as tubing for pacing leads or other catheter materials. Other technologies to allow continuous NO (nitric oxide) release could be employed, and have been mainly described by Dr. Meyerhoff's previous research which he disclosed at a recent Forum presentation at Meditronic Cardiac Surgery. Other than the ability of releasing nitric oxide, this leads will indistungishable from existing leads. Once implanted into the human body, pacing leads typically show signs of thrombus formation, and subsequently scar formation (fibrosis). This often leads to complicated lead removal procedures. In case of NO-releasing leads, the thrombus formation is attenuated or completely avoided, which subsequently will reduce encapsulation and fibrosis of the leads, and dramatically enhance removability.							

http://intranet4.corp.medtronic.com/legal

	Sale or Publication (Needed to establish the date of any printed publication, public use or sale, since no U. S. patent							
	application may be filed after one year from such date.)							
	ā.	If a device has been offered, or will be offered for sale, or used for profit or otherwise publicly disclosed, state will and to whom delivered and how used?						
	b.	Has a printed description of this invention been made available to and was use restricted (e.g. licensing agreement, non-disclosure	persons outside the company? How and whe agreement, proprietary legends, etc.)?					
	Inventor(s) Signature(s) (REQUIRED):							
•	Signat	ure de fial	Date 2 2 22					
•	Signat	ure aniel fiff	Date 12 -2-7 07_					
•	Signat	ure runiel fizz	Date 12 -2 7 -02_					
•	Signat	ure aniel fif	Date 12 -2 -7 07_					
•	Signat	Manager's Comments	Date 12 -2-7 07_					
•			Date 12 -2-7 07_					
	How is	Manager's Comments	<u>12 -2 -7 07 -</u>					
	How is	Manager's Comments this invention important to your products, plans or goals?	Date 12-27-02 26DEC02					
	How is	Manager's Comments this invention important to your products, plans or goals? er's Signature (REQUIRED)	<u>12 -2 -7 07 -</u>					
1	How is Manag Signati	Manager's Comments this invention important to your products, plans or goals? er's Signature (REQUIRED)	26DEC02					

Manager: Please forward to Patent Section of Law Department, LC340, upon completion of your review.

EXTRACTION OF LEADS REMAINS A RELEVANT, AND
LARGEY UNSCLUED, CLINICAL ISSUE. THIS CONCEDT

PROVIDES A LOW COST MEANS OF MANAGEING
FIBROSIS. THE CONCEPT MAY ALSO HAVE
UTILITY FOR PREVENTING FOULING OF SENSORS
AND DRUG DELIVERY CATHETERS.

OM NOV. 17. 2005 9:56AM 76	35146982 MEDTRONIC : : : : :	,	407; -P. 14-1-1-1-
NO-RELEASING 1	EAD ON CATHETE		
Nimo oxide ha	the whilth by		
	the whiting to	never dur	Torno man
Technologies w	nich are curren	My being up	al to cener
ND - 4 / page 10	1400		
	uson (loading o	+ Ny shecis	av ruo
polymer or gen	wahy a susta	need wear	usin ende
	4 4 4 4 4 4		
you a	unos as desení	net ly	
M of mounte	in) could be	in corporate	d into
27/21 102 11	20 10 10 - 11		
and the second	rodies or call	ex poone	(sincone,
poly wethours	2) or other pol	men ner	to ever
Milni	40.00		
, <u>, , , , , , , , , , , , , , , , , , </u>	s prevent c	other ->	mons
and ulhmal	ely entource	REMOVARS	LAY
A MARQUE	010000	,	
11.000000	releane would	se more	elemente
		1/0 / 1	
	////	NO-loaded	
		, or free	
	- ANO	NO-Hlean	2
	or	NO serecal	7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
	tri	in body hear	
an erang caramanan ar a managan ar farang	·	odnets	
nessed & Understood by me,	Date Invented by ()	(53.00 ln.	To Page No.4/
I mAGA	11/15/15		13-02
7 / 1	Recorded by, Si	'A "-	17.02